What is Cytonics?
Cytonics Corporation, headquartered in Jupiter, FL, is a biopharmaceutical research and development Company dedicated towards engineering diagnostics and treatments for osteoarthritis. To-date, the company has developed an impressive portfolio comprising a biomarker assay and two medical devices for treating cartilage damage due to arthritic decay. The company is currently engineering a recombinant protein version of its core technology, which will be the first “off-the-shelf” treatment for osteoarthritis.
$20M raised from public and private investors
Cytonics has over 100 current shareholders of common and preferred stock
Raised last round
Cytonics raised $794,000 in the last round of financing this year
Watch the webinar recording
Reserve Shares Today!
Be part of the relief for OA
Cytonics has received over $15M in funding to-date, including $1.8M in grants from the National Institute of Health and a $4M investment from Synthes (a Johnson and Johnson company). We are seeking to raise $1M by conducting a public offering under Regulation CF. Proceeds will be used to advance our lead drug candidate, Cyt-108, into FDA clinical trials and fund ongoing business operations.
Cytonics Corporation is offering securities under Regulation CF and Rule 506(c) of Regulation D through SI Securities, LLC (“SI Securities”). The Company has filed a Form C with the Securities and Exchange Commission in connection with its offering, a copy of which may be obtained at: https://seedinvest.com/cytonics